Management and Treatment of Depression

Jessica Grant, MD, FAAP
Founder, Partner, and Pediatrician, Manhattan Valley Pediatrics, New York, NY
Project TEACH, Primary Care Champ









Jessica Grant, MD, FAAP

Founder, Partner, and Pediatrician, Manhattan Valley Pediatrics, New York, NY

Project TEACH, Primary Care Champ



Disclosures

"My spouse/partner and I have the following relevant financial relationship with a commercial interest to disclose:





POLL

Should Pediatric Primary Care Providers treat major depressive disorder in teens?

- 1. Yes. Always.
- 2. No. Never.
- 3. Yes but only for mild depression.
- 4. Yes but only to bridge care while patients wait for a psychiatrist.




Let's continue where we left off...



Clinical Assessment Flowchart.

Preparation for Managing Depression in PC

Preparation through increased training, establishing mental health linkages, and increasing the capacity of practices to monitor and follow-up with patients with depression



Rachel A. Zuckerbrot et al. Pediatrics doi:10.1542/peds.2017-4081

©2018 by American Academy of Pedatrics Evaluation Positive for Depression: Mild, Moderate, Severe, or Depression with Comorbidities

- (1) Evaluate safety and establish safety plan
- Evaluate severity of depression symptoms (See^a)
-) Patient and/or family education (See^b)
- (4) Develop treatment plan based on severity-review diagnosis and treatment options with patient and/or family



Initial Management

- A. Decide if Mild, Moderate or Severe
- B. Establish a Safety Plan
- C. Educate Patient and Family
- D. Develop a treatment plan based on severity



A. How to Decide?

MILD

MODERATE SEVERE

- Clinical impressions from interview
- Standardized rating scales scores
- Number of DSM-5 criteria
- Degree of impairment from baseline
- Safety issues (suicidality, self-injury)



B. Safety Planning

- Assess current risk ASQ screen
- If safe to go home, have parents "sanitize" the home
- Make a written plan
 - NOT A PROMISE TO NOT HARM
 - Hierarchy of support system
 - comforting activities: music, art, sports, etc.
 - support systems: when to contact.... friends, parents, PCP, 911



C. Patient and Family Education

- Explaining depression as a common and treatable condition is one of the most important steps to be done in primary care
- Written materials can go a long way in helping to keep them engaged in the mental health process
 - NAMI FAMILY GUIDE
 - GLAD-PC Toolkit Handouts





C. Patient and Family Education: Basic Interventions

- Behavioral Activation
- Exercise
- Nutrition
- Spend time outside (commune with nature)
- Hang out with supportive friends
- Spiritual or other supportive community
- Altruism (volunteer opportunities)
- Sleep
- Limit screen time/ social media




D. Develop a Treatment Plan Based on Severity


Now we go to Part II of the guidelines and the second flowchart



D. Develop a Treatment Plan Based on Severity



Amy H. Cheung et al. Pediatrics doi:10.1542/peds.2017-4082





If improved after 6-8 weeks


- Continue medication for 1 year after full resolution of symptoms (based on adult literature)
 AACAP recommends monthly monitor for 6 months after full remission
- Continue to monitor for 6 to 24 months with regular follow-up whether or not referred to mental health specialist
- . Maintain contact with mental health specialist if such treatment continues



Managing Mild Depression



Clinical Assessment Flowchart







Active Monitoring & Close Follow-Up


hings you can do to help y me: Date:		<u></u>			
Instructions: When people a self-care goals you can take an a two of the areas below and set a the boxes rate how likely you are can follow through on your goal.	active role in h goal. Make su to follow throu	elping your ire the goal ugh on the	self feel bet l is clear and goal(s) you	ter more qui d reasonable set. If you a	ickly. Choose one or e. In the space below ire not very sure you
Stay Physically Active		Plea	edule isant vities		Eat Balanced Meals
Each week during the next month I will spend at least days doing the following physical activity for minutes.	Even though I may not feel motivated I will commit to schedulingfun activities each week for the next month. They are			Even if I don't feel like it, I will eat balanced meals per day to include (Choose healthy foods.) Small Goals & Simple Steps The problem is: My goal is: Step 1: Step 2: Step 3:	
(Pick a specific date and time and make it reasonable!)					
Spend Time With People Who Can Support You					
During the next month I will spend at least days for at least minutes at a time with: doing:					
doing doing: (What?)					
(e.g. talking, eating, playing)					
How likely are you Not Likely 1 2	to follow throu	igh with the	rse activities	************	r next visit? Very Likely
What might get in th	e way of your o	ompleting	these activiti	es prior to y	our next visit?



Managing Moderate to Severe Depression



Clinical Assessment Flowchart



- Continue medication for 1 year after full resolution of symptoms (based on adult literature)
 AACAP recommends monthly monitor for 6 months after full remission
- Continue to monitor for 6 to 24 months with regular follow-up whether or not referred to mental health specialist
- 3. Maintain contact with mental health specialist if such treatment continues





Referral for Evidence-based Therapy

- Explain to the family why you are referring them.
- Explain what the provider will do, use names and describe office if possible.
- Explain your continued role in their care.
- Communicate with referral provider.
- Establish roles and responsibilities with mental health provider.



Psychotherapy for Depression

- Cognitive Behavioral Therapy (CBT)
- Interpersonal psychotherapy- Adolescent (IPT-A)
- Other therapies are difficult to manualize and test in a RCT (does not mean that they are ineffective)



POLL

If your patient has been referred to specialty mental health, should you make a depression follow-up appointment in primary care?


- 1. Yes. Always.
- 2. No. Never.
- 3. Yes, just to make sure they are engaged in treatment, and then no need to follow-up after that.



Yesterday I explained something so bleak to my therapist she asked me if we could pause for a minute so she could think about it. I'm getting close to winning therapy I can feel it in my bones.



Clinical Assessment Flowchart



- Continue to monitor for 6 to 24 months with regular follow-up whether or not referred to mental health specialist
- Maintain contact with mental health specialist if such treatment continues





Cognitive Behavioral Therapy


GETS KIDS MOVING and BUILDS SKILLS

- Behavioral Activation (Go watch the other kids play basketball even if you are too tired and not interested).
- Cognitive restructuring (The world is not out to get you. That is the depression talking.)
- Coping skills training (What can you do next time when you get into a fight instead of trying to hurt yourself?)
- Stress management (Deep breathing, listening to music, etc).



Psychopharmacotherapy for Depression

SSRIs (Selective Serotonin Reuptake Inhibitors)



First-line Treatment in Adolescent Depression



Choosing an SSRI

FDA Approval for MDD in Teens?

- Fluoxetine
- Escitalopram

RCT Evidence for MDD in Teens?

- Fluoxetine
- Escitalopram
- Sertraline
- Citalopram

FDA Approval for other Disorders in Teens?

- Fluoxetine
- Sertraline
- Fluvoxamine



Other Considerations

- Prior treatment history
- Family member response
- Family preference
- Clinical experience



Treatment of Adolescent Depression Study (TADS)

March et al, 2004

- 439 adolescents, 12-17 years old, 13 sites, 12 weeks
- Study groups:
 - Medication (fluoxetine) alone: 60.6%
 - Cognitive Behavioral Therapy alone: 43.2% (not statistically different from placebo at 12 weeks)
 - CBT + fluoxetine: 71%
 - Placebo: 34.8%




CBT for Relapse Prevention

 Adding CBT after initial response to meds will keep improvement for longer (increase time to relapse)

 CBT booster sessions also help prevent relapse and deterioration of CBT skills



Follow-Up



Amy H. Cheung et al. Pediatrics doi:10.1542/peds.2017-4082

©2018 by American Academy of Pediatrics



If improved after 6-8 weeks

- 1. Continue medication for 1 year after full resolution of symptoms (based on adult literature) AACAP recommends monthly monitor for 6 months after full remission
- Continue to monitor for 6 to 24 months with regular follow-up whether or not referred to mental health specialist
- Maintain contact with mental health specialist if such treatment continues

FOLLOW UP

- Doing well = full remission! → Educate about the natural history of depression, the goal is treatment for ~12 months after improvement before taper and D/C
- Partial response → increase dose for full trial, consider augmentation if at maximum dose or add CBT
- Doing poorly → Reassess diagnosis, change dose or medicine, add evidence-based psychotherapy
- Call the Project TEACH Hotline for consultation and/or referral to Mental Health



SSRI How-To: Part I

- Try to start with a first-line medication (FDA approved) unless other considerations take precedence
- Start at a dose lower than the expected therapeutic dose (e.g fluoxetine 5 or 10 mg instead of 20 mg or escitalopram 5 mg instead of 10 mg)
- If there are no side effects, go up in a week.
- Warn families that the early doses are to acclimate and test the waters.
- Get to a therapeutic dose in 2-4 weeks (clinical judgement).
- Patients should respond somewhat to therapeutic dose in 2-3 weeks.
- If no response, increase dose.
- If some response, wait 4-6 weeks (for full response to take effect) to decide if dose should be increased.



SSRI How-To: Part II

- Fluoxetine (longest acting)
 - Start at 10mg (can even start at 5mg)
 - Increase by 10mg increments (can go by 5mg)
 - Therapeutic range: 20-60mg, can go up to 80mg
- Escitalopram
 - Start at 5mg
 - Increase by 5mg increments
 - Therapeutic range: 10-20mg
- Sertraline
 - Start at 25mg (can even start at 12.5mg)
 - Increase by 25mg increments (can increase by 12.5mg)
 - Therapeutic range: 25-200mg



SSRI How-To: Part III

- Monitor for side effects
- Monitor for suicidality
- Monitor for improvement in symptoms and functioning
- If patient does not respond at higher doses of SSRI, consider change of medication
- Next step in medication is to try a different SSRI (not to switch classes)
- How to switch from one medication to another (cross-tapering vs. stopping and starting, cross-tapering slowly vs cross-tapering quickly, etc.) depends on many factors including but not limited to which specific SSRIs, the side effects, the response, and the clinical picture > CALL PROJECT TEACH



What Could Go Wrong: Side Effects

- GI symptoms: resolve in a few weeks
- Serotonin syndrome: Start low and titrate up
- Sexual: discuss at onset and at follow up visits
- Suicidality: Medication-induced versus medication undertreatment?
- Activation and Mania

See Glad PC Toolkit for complete list



SSRI Activation in Youth

- Activation represents a hyperarousal event: increase in activity, impulsivity, disinhibition, restlessness and insomnia.
- Antidepressant-related activation emerges early in treatment or following an increase in dose, and symptoms resolve when the antidepressant dose is decreased or when the antidepressant is discontinued
- Some evidence suggests slower titrations and lower doses can help
- Hypomania and mania are rare but some activation symptoms in youth treated for MDD is not so rare



What else could go wrong

 Patients often stop meds for "side effects" that are actually part of the primary disorder – fatigue, appetite changes, etc.

 Recurrence/relapse – more likely if you treat partially (too low a dose or too short a duration)



Danielle



How to Decide When to Use Any Medicine

- Severity of illness
- Patient preference
- Monitor the trajectory of the illness
- Remember the risks of NOT treating
- Assess the risk-benefit ratio with the family



Barriers to Success



Time:

Schedule appropriately
Bill for your valuable time

Parental Resistance:

Bring up medication early

Discussed risk of not treating

Emphasize informed decision-making

Knowledge and Confidence:

Start small and "easy"

Use Project Teach

Provider Fatigue:

Decompress, Discuss, Delegate



The Boxed Warning



Boxed Warnings

- FDA requires a boxed warning when a medication causes a serious undesirable effect
- Over 600 medications carry boxed warnings
- Over 40% patients in outpatient setting receive at least 1 medication with a boxed warning

Wagner 2006



Antidepressant Boxed Warning

2004

- Warning up to the age of 18
- Warned of increased suicidality
- Called for weekly visits for 4 weeks, every other week visits for another 8 weeks, and then monthly visits

2007

- Warning up to age 24
- Risk must be balanced with the clinical need.
- Risk of suicide from depression itself highlighted.
- Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.



FDA Boxed Warning on Antidepressants

 Prompted by warning of increased suicide risk in adolescents treated with *paroxetine*, by British MHRA in June 2003

 FDA pooled data from 24 studies examining antidepressant use in children for depression and anxiety disorders



Limitations of the FDA review

- Limitations
 - Post-hoc analyses, multiple sub-analyses
 - none of original 24 studies were designed to evaluate this
 - Few events of "suicidality" (78/4400)
 - Substantial differences between studies in classification
 - Noncompliance not considered
 - Patients with severe pathology excluded




FDA Analysis Results

- September 2004,FDA reports increase in suicidality on medication
 - Suicidality defined as
 - new onset SI
 - worsening of SI
 - new or increased suicidal behaviors

3.8% on SSRIs vs 2.1% on placebo




Unintended Consequences





Unintended Consequences





Unintended Consequences

- Rates of antidepressant drug prescriptions declined by 50%
- Rate of diagnosis of MDD reduced by 40%
- Increase in psychotherapy did NOT occur as expected
- Increased utilization of Benzo and antipsychotic medications
- Studies suggested actual increased rate of suicide

Formaro 2019



TAKE HOME POINT #1: SUICIDAL RISK ON ANTIDEPRESSENTS

- No deaths / no completed suicides
- Across ALL studies with 4400 children and adolescents



TAKE HOME POINT #2:SUICIDE RISK

Increased risk of suicide with untreated depression



In Summary: Management of Depression in Children and Adolescents

- Depression in children & adolescents is common, identifiable and treatable
- Psychotherapy is acceptable/emphasized as a first line in mild/moderate MDD
- Based on FDA meta-analysis, share with families:
 - There is a 2-4% RISK of SI on meds vs 1-2% on placebo
 - TADS study shows a 60-70% chance of improvement of MDD with medication treatment



In Summary: Management of Depression in Children and Adolescents (continued)

- Fluoxetine and Escitalopram are FDA approved to treat depression in adolescents (although may have good reason to use others)
- Educate families to watch for and report :
 - Increase in agitation or uncharacteristic behavior change or suicidal/self-injurious thoughts/behaviors and how to get help
- Monitor closely for side effects and for improvement



The Take-Away...

- Depression can be managed in a Primary Care setting
- PCPs are the first line of defense: accessibility, trusted, established knowledge of the patient
- These are the most grateful of families
- The mental health crisis is our call to step up to the plate
- Do not make kids suffer!



